Objective-The intestinal microbiota is emerging as a clinically relevant modulator of atherosclerotic risk. Reverse cholesterol transport (RCT) is an atheroprotective metabolic pathway. How the microbiota impacts RCT has not been investigated. Therefore, the aim of this study was to characterize (cholesterol) metabolism and RCT in germ-free mice compared with conventional mice. Approach and Results-In chow-fed germ-free mice, plasma cholesterol was unchanged, whereas liver cholesterol content was higher (1.5-fold; P<0.05) than in conventional controls. Biliary secretion of cholesterol (2-fold; P<0.001) and bile acids (3-fold; P<0.001) was substantially increased in the germ-free model, whereas fecal neutral sterol excretion was unaltered, and fecal bile acid excretion was decreased (P<0.01). However, fecal bile acid profiles of germ-free mice were dominated by the presence of β-muricholic acid (P<0.001), pointing toward a higher contribution of the alternative acidic pathway to total bile acid synthesis in these mice. As expected, secondary bile acids were absent in the germ-free model. In vivo macrophage-to-feces RCT was increased >2-fold (P<0.01) in the absence of intestinal bacteria. Conclusions-These data demonstrate that the absence of the intestinal microbiota stimulates RCT >2-fold. Stress could potentially explain these findings, 7 but plasma corticosterone levels were comparable between conventional and germ-free mice making this possibility less likely (1466±219 versus 1496±159 nmol/L, respectively).
vidence is accumulating that the intestinal microbiota has a substantial impact on the (patho)physiological regulation of metabolism. The human microbiota in general represents not only the first line of contact with the environment, but intestinal bacteria in particular also express ≈100-fold more genes than present in the human genome. 1 The intestine is one of the key organs in the regulation of cholesterol metabolism with relevance for atherosclerotic cardiovascular disease. Enterocytes are responsible for cholesterol absorption, can synthesize cholesterol, and form high-density lipoprotein particles. 2 As a precedence for the impact of bacteria on cardiovascular disease, it was demonstrated that specific diet-microbe-host interactions can enhance experimental atherosclerosis via the coordinate production of the proatherosclerotic metabolite trimethylamine-N-oxide. 3 Subsequently, trimethylamine-N-oxide was also identified as a prospective biomarker for the future development of cardiovascular disease events in the general population, further stressing the relevance of the microbiota for human disease. 4 In addition, bacteria can modulate bile acid (BA) metabolism and thereby impact cholesterol turnover. 5 In conventional mice, the intestine was shown to contribute to reverse cholesterol transport (RCT), a key atheroprotective pathway. 6 However, the impact of the intestinal microbiota per se on RCT has not been determined. Therefore, the aim of the present work was to establish the importance of the intestinal microbiota for RCT by comparing conventional with germ-free mice.
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Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results
First, we characterized cholesterol metabolism in germ-free mice compared with conventional controls. Both groups had similar body weights (21.3±1.1 versus 21.4±1.5 g). Although plasma total cholesterol (Figure [A] ) and triglyceride levels (0.26±0.02 versus 0.28±0.02 mmol/L) were comparable between groups, FPLC profiles showed a discrete shift toward higher low-density lipoprotein-cholesterol and lower high-density lipoprotein-cholesterol in germ-free animals ( Figure IA Stress could potentially explain these findings, 7 but plasma corticosterone levels were comparable between conventional and germ-free mice making this possibility less likely (1466±219 versus 1496±159 nmol/L, respectively).
Therefore, we also characterized bile acid metabolism under germ-free conditions more in detail. Bile flow was significantly increased compared with conventional mice (2-fold; P<0.001; Figure IIA in the online-only Data Supplement). Although fecal mass excretion of bile acids was lowered, there were striking shifts in the fecal bile acid profile in germ-free mice. As expected, secondary bile acids such as deoxycholic acid and ω-muricholic acid (ω-MCA) were absent. On the other hand, the percentage of fecal cholic acid was higher (P<0.05), and the contribution of β-muricholic acid (β-MCA) was increased by 4.5-fold in mice lacking microbiota (P<0.001; Figure IIA and IIB in the online-only Data Supplement). Quantification of hepatic bile acid synthesis gene expression (Table) mice, whereas Cyp27a1, which initiates the alternative acidic pathway with β-MCA as end product, remained unchanged. mRNA expression of fibroblast growth factor 15 (Fgf15) in the terminal ileum was 2.6-fold increased in the germ-free model (Table; P<0.05).
Discussion
The results of this study demonstrate that complete absence of the microbiota (1) does not influence plasma cholesterol levels or mass fecal neutral sterol excretion, (2) decreases fecal BA excretion, and (3) significantly increases RCT, mainly within the fecal BA fraction. Previous work indicated that differences in cholesterol metabolism between germ-free and conventional mouse models are variable; the observed phenotypes conceivably depend on diet, genetic background, and the respective composition of the microbiota in the conventional control groups. [8] [9] [10] Thus far, decreased plasma cholesterol, both increased and decreased liver cholesterol, and higher fecal neutral sterol output were observed in germfree mice fed western-type or high-fat diets. 10, 11 Interestingly though, the most significant differences between conventional and germ-free mice in our experimental system were seen in bile acids.
The changes in BA metabolism occurring in the germ-free mice are, however, rather complex; on the one hand, there is increased biliary BA secretion, on the other decreased fecal excretion. This difference can be explained by increased BA reabsorption in the terminal ileum of germ-free mice, a notion in general consistent with the increased expression of the farnesoid X receptor (FXR) target gene Fgf15 that we observed in our study. However, the 2.6-fold increase in Fgf15 expression in the germ-free model also indicates another relevant change in BA metabolism in these mice. Mice lacking intestinal bacteria have 2 principal BA species, the more hydrophobic taurocholic acid, which is an FXR agonist, 12 and the hydrophilic tauro-β-muricholic acid (T-β-MCA), which has been characterized as an FXR antagonist. 13, 14 Increased expression of the FXR target gene Fgf15 indicates thus that relatively more taurocholic acid, the FXR agonist, is taken up over T-β-MCA, the FXR antagonist. Indeed, previous work demonstrated a substantially higher affinity of ASBT, the apical transporter responsible for intestinal BA reuptake, for taurocholic acid compared with T-β-MCA. 15 Since due to the absence of bacteria no secondary BA are formed in germ-free mice, there is no means of taking up conversion products of T-β-MCA in the colon, thus resulting in substantial amounts of T-β-MCA being excreted into the feces. In agreement, hepatic gene expression analysis indicated that the expression of Cyp27a1 is unchanged, pointing toward a higher relative contribution of the alternative acidic bile acid synthesis pathway with its end product T-β-MCA in the germ-free mice. It is thus to be expected that in the absence of intestinal bacteria relatively more macrophagederived cholesterol is converted into T-β-MCA, which is then preferentially excreted into the feces. These mechanisms can in our view explain how increased RCT mainly in the BA fraction occurs in germ-free mice with decreased mass fecal BA excretion. However, more experimentation seems required to fully substantiate this proposed model.
Further, it has to be noted that converting chenodeoxycholic acid into β-MCA occurs in mice but not in humans. 16 Therefore, further studies are needed to investigate whether the results of our current study can be translated to a clinical setting in humans. In addition, also about bile acid metabolism in germ-free mice, variable data have been generated, likely dependent on genetic background and diet, for example, unchanged and decreased fecal bile acid excretion were reported. 8, 14 Clearly, also with respect to this issue, more studies are needed to better characterize the response of different germ-free mouse lines to varying experimental conditions. In summary, our present work supports the importance of the intestinal microbiota for metabolic regulation and extends previous observations to RCT, a pathway with a high relevance for atherosclerosis protection. Specific targeting of the intestinal microbiota with the aim to modulate bile acid metabolism bears therapeutic potential with the goal to prevent and treat cardiovascular disease.
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